Other trials evaluating bevacizumab (anti-VEGF) in combination with everolimus (mTOR inhibitor) have demonstrated only modest clinical benefit (CBR = 12%)25, although sunitinib (VEGFR-TKI) is also currently being investigated in MPNST (NCT 01402817). This evidence concerns the gene MTOR and malignant peripheral nerve sheath tumor.